Tezepelumab Home Use Study (PATH-HOME)

A Multicenter, Randomized, Open-label, Parallel Group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector With Home-administered Subcutaneous Tezepelumab in Adolescent and Adult Subjects With Severe Asthma (PATH-HOME)

This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered subcutaneously in the clinic and in an at-home setting.

Study Overview

• Status: Completed
• Conditions: Asthma
• Intervention / Treatment: Biological: Tezepelumab (AI); Biological: Tezepelumab (APFS)

Detailed Description

The study will consist of a screening/run-in period of up to 2 weeks and a treatment period of 24 weeks, followed by a post-treatment follow-up period of 12 weeks. During the treatment period, one dose of 210 mg tezepelumab will be administered via a single-use APFS or AI subcutaneously (SC) every 4 weeks (Q4W) starting at Visit 2 (Week 0) until Visit 7 (Week 20). Subjects will be administered tezepelumab at the site during Visits 2 (Week 0), 3 (Week 4), 4 (Week 8) and 7 (Week 20). At-home administration of tezepelumab will occur during Visit 5 (Week 12) and Visit 6 (Week 16). Each device will be assessed separately using descriptive presentations.

• Study Type: Interventional
• Enrollment (Actual): 216
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Quebec, Canada, G1V 4W2
    • Research Site
  • Quebec, Canada, G1V 4G5
    • Research Site
  • Alberta
    • Calgary, Alberta, Canada, T2N 1N4
      • Research Site
  • Ontario
    • Ajax, Ontario, Canada, L1S 2J5
      • Research Site
    • Burlington, Ontario, Canada, L7N 3V2
      • Research Site
    • Mississauga, Ontario, Canada, L5A 3V4
      • Research Site
    • Ottawa, Ontario, Canada, K1G 6C6
      • Research Site
    • Windsor, Ontario, Canada, N8X 2G1
      • Research Site
  • Quebec
    • Montreal, Quebec, Canada, H3G 1L5
      • Research Site
    • Trois-Rivieres, Quebec, Canada, G8T 7A1
      • Research Site
• Japan
  • Chuo-ku, Japan, 103-0027
    • Research Site
  • Fukuoka-shi, Japan, 811-1394
    • Research Site
• Poland
  • Białystok, Poland, 15-430
    • Research Site
  • Kraków, Poland, 31-011
    • Research Site
  • Poznań, Poland, 60-685
    • Research Site
  • Poznań, Poland, 60-693
    • Research Site
  • Strzelce Opolskie, Poland, 47-100
    • Research Site
  • Tarnów, Poland, 33-100
    • Research Site
  • Wieluń, Poland, 98-300
    • Research Site
  • Wrocław, Poland, 53-301
    • Research Site
• United States
  • Alabama
    • Hoover, Alabama, United States, 35244
      • Research Site
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Research Site
  • California
    • Northridge, California, United States, 91324
      • Research Site
    • Palm Desert, California, United States, 92260
      • Research Site
    • Westminster, California, United States, 92683
      • Research Site
  • Florida
    • Tampa, Florida, United States, 33607
      • Research Site
  • Georgia
    • Savannah, Georgia, United States, 31406
      • Research Site
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Research Site
  • New Jersey
    • Northfield, New Jersey, United States, 08225
      • Research Site
  • Ohio
    • Cincinnati, Ohio, United States, 45231
      • Research Site
  • Oklahoma
    • Edmond, Oklahoma, United States, 73034
      • Research Site
  • Oregon
    • Medford, Oregon, United States, 97504
      • Research Site
  • Texas
    • Dallas, Texas, United States, 75235
      • Research Site
    • McKinney, Texas, United States, 75069
      • Research Site
    • San Antonio, Texas, United States, 78229
      • Research Site
    • San Antonio, Texas, United States, 78221
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 years to 76 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female, age 12 to 80 years.
• Documented physician-diagnosed asthma for at least 12 months.
• Evidence of asthma as documented by post BD (albuterol/salbutamol) reversibility of FEV1 ≥ 12% AND ≥200 mL (15-60 min after administration of 4 puffs of albuterol/salbutamol), documented either: in the previous 12 months prior to V1, OR demonstrated at V1, V1A, or at V2.
• Documented history of current treatment with medium- or high-dose ICS for at least 6 months and at least one additional asthma controller medication according to standard practice of care. ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily.
• Morning pre-BD FEV1 of >50% predicted normal at Visit 1, Visit 1A, or Visit 2.

Exclusion Criteria:

• Clinically important pulmonary or systemic diseases other than asthma.
• History of cancer except basal cell carcinoma, squamous cell carcinoma, or in situ carcinoma of the cervix within 12 months prior to Visit 1.
• Acute upper or lower respiratory infection requiring antibiotics or antiviral medications finalized <2 weeks before Visit 1 or during screening/run-in period.
• A helminth parasitic infection diagnosed within 6 months that is untreated or is unresponsive to the standard of care.
• Smoking history of ≥10 pack years, (includes vaping and e-cigarettes)
• History of chronic alcohol or drug abuse.
• Tuberculosis requiring treatment within 12 months prior to V1.
• History of HIV, Hepatitis B or Hepatitis C.
• Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives.
• Bronchial thermoplasty in 24 months prior to V1.
• Anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy.
• Evidence of active liver disease (e.g. jaundice, AST, ALT or ALP >2 times upper limit of normal), ongoing liver disease or inexplicably elevated liver chemistry values.
• Pregnant, breastfeeding or lactating women.
• Non-leukocyte depleted whole blood transfusion in 120 days prior to visit 1.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tezepelumab (AI); Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.	Biological: Tezepelumab (AI); Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
Experimental: Tezepelumab (APFS); Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).	Biological: Tezepelumab (APFS); Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type	Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.	Week 0, Week 4, Week 8, Week 12, Week 16, Week 20

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction	Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional. Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.	Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Proportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)	Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints). Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.	Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score	The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.	Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Serum Trough Concentrations	PK serum samples were collected pre-dose on dosing visits	Baseline (Week 0), Week 4, Week 20 and Week 24 (EOT)
Anti-drug Antibodies (ADA)	Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at >=2 post-baseline assessments (with >=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive	Pre-treatment on dosing days until end of follow-up (Week 36) per protocol

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Amgen
• Investigators: Principal Investigator: Sady A Alpizar, MD, Clinical Research Trials of Florida, Inc.

Publications and helpful links

General Publications

• Alpizar S, Megally A, Chen C, Raj A, Downie J, Colice G. Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma. J Asthma Allergy. 2021 Apr 19;14:381-392. doi: 10.2147/JAA.S305114. eCollection 2021.

Helpful Links

• Statistical Analysis Plan (SAP)
• Protocol

Study record dates

Study Major Dates

• Study Start (Actual): May 21, 2019
• Primary Completion (Actual): June 5, 2020
• Study Completion (Actual): June 5, 2020

Study Registration Dates

• First Submitted: April 30, 2019
• First Submitted That Met QC Criteria: May 29, 2019
• First Posted (Actual): May 30, 2019

Study Record Updates

• Last Update Posted (Actual): July 29, 2021
• Last Update Submitted That Met QC Criteria: July 9, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: Asthma, Severe Uncontrolled Asthma
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Physiological Effects of Drugs; Immunologic Factors; Antibodies, Monoclonal
• Other Study ID Numbers: D5180C00011

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No